Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARPA study of AZD9291 tolerability and quality of life in advanced EGFR-mutant NSCLC after prior EGFR-TKI
2015-001970-16Phase 2Completed
- Sponsor
- APOT
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by APOT. Started Jan 2021; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-001970-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001970-16.